Enveric Biosciences shares rise 13.47% premarket after closing $1.5M direct offering and issuing warrants for product development.

Enveric Biosciences surged 13.47% in premarket trading following the announcement of a $1.5 million registered direct offering and concurrent private placement of warrants. The company sold 328,802 shares at $4.41 per share and issued Series G and H warrants exercisable at $4.16 per share, with proceeds earmarked for product development, working capital, and general corporate purposes. The transaction, executed on January 28, 2026, via H.C. Wainwright & Co., reflects enhanced investor confidence in the biotechnology firm’s pipeline, including its lead candidate EB-003, which targets psychiatric and neurological disorders. The warrants’ immediate exercisability and varying expiration terms (five years for Series G, 18 months for Series H) further signaled strategic capital-raising flexibility. The move aligns with Enveric’s focus on advancing neuroplastogenic therapeutics without hallucinogenic effects, positioning the stock for potential growth amid pipeline development.